High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response

M. A. Ferro*, D. Gillatt, M. O. Symes, P. J B Smith

*Corresponding author for this work

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

High-dose intravenous estrogen therapy was shown to be effective in relieving bone pain due to metastatic disease in 22 of 29 (75.9 %) men with advanced hormone-resistant prostate cancer. This clinical response was accompanied by significant falls in serum prostate-specific antigen (PSA) levels in 13 (44.8%) patients. It is suggested that this clinical benefit is due to a direct inhibitory effect of estrogen on prostate cancer cells.

Original languageEnglish
Pages (from-to)134-138
Number of pages5
JournalUrology
Volume34
Issue number3
DOIs
Publication statusPublished - 1989
Externally publishedYes

Fingerprint Dive into the research topics of 'High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response'. Together they form a unique fingerprint.

Cite this